Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial
- 26 November 2018
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 95 (1), 210-218
- https://doi.org/10.1016/j.kint.2018.08.039
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The Role of Th17/IL-17 in the Pathogenesis of Primary Nephrotic Syndrome in ChildrenKidney and Blood Pressure Research, 2013
- Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosusArthritis Research & Therapy, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Clinical trial of focal segmental glomerulosclerosis in children and young adultsKidney International, 2011
- Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndromeClinical and Experimental Nephrology, 2010
- T regulatory cell function in idiopathic minimal lesion nephrotic syndromePediatric Nephrology, 2009
- The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndromePediatric Nephrology, 2009
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?Pediatric Nephrology, 2004